毒性更小、更有效——默克尔细胞癌患者的双赢治疗
默克尔细胞癌(MCC)复发率超过三分之一,死亡率达33%至46%,传统治疗手段(广泛手术、放疗、全身治疗)侵袭性强且毒性大。近期在局部管理、复发早期检测和全身治疗三方面的进展使得MCC治疗更有效且毒性更低。本文为少见MCC的医生提供资源和指南,以助优化初始治疗和参与长期管理。
要点
- MCC复发率超三分之一,死亡率33%至46%,需重视高危管理。
- 近期进展聚焦局部管理、复发早期检测和全身治疗三方面。
- 为不常接诊MCC的医生提供资源和指南,优化初始治疗与长期管理。
核心结论
- 近期多项进展使MCC管理更有效且毒性更低。
研究设计与样本
- 本文为观点类文章,未报告系统检索方法或样本量。
主要发现
- MCC复发率超过三分之一,死亡率33%至46%。
- 近期进展涉及局部管理、复发早期检测和全身治疗三方面。
临床怎么用
- 为不常接诊MCC的医生提供资源和指南,以优化初始治疗并参与长期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Merkel cell carcinoma (MCC) is an aggressive skin cancer that recurs in more than one-third of cases, with reported mortality rates of 33% to 46%. Given this high-risk situation, MCC is often managed with therapies that are aggressive and potentially toxic: extensive surgery, radiation therapy (RT), and systemic therapy. Fortunately, recent advances in multiple realms now allow MCC management to be more effective and less toxic. In this Viewpoint, we highlight 3 recent developments relating to progress in local management, early detection of recurrent disease, and systemic therapy. Although it is not practical for physicians who rarely see patients with MCC to remain up-to-date on the details of management, herein we provide resources and guidelines to help physicians ensure optimal initial care and participate in longitudinal treatment of patients with MCC.
引用
- Nghiem P, Park SY. Less Toxic, More Effective Treatment-A Win-Win for Patients With Merkel Cell Carcinoma. JAMA Dermatol. 2019. PMID: 31483436. doi:10.1001/jamadermatol.2019.2584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。